Dr. Kumar has been President and CEO since September 2001, and has been a Director since September 2000. Previously, Dr. Kumar was Vice President of Life Sciences of Acacia Research Corp. (NASDAQ: ACRI). From January 1999 to February 2000, Dr. Kumar was the founding President and Chief Executive Officer of Signature BioSciences, Inc., a life science company developing technology for advanced research in genomics, proteomics and drug discovery. From January 1998 to December 1999, Dr. Kumar was an Entrepreneur in Residence with Oak Investment Partners, a venture capital firm. From October 1996 to January 1998, Dr. Kumar was a Senior Manager at IDEXX Laboratories, Inc., a biotechnology company. From October 1993 to September 1996, Dr. Kumar was Head of Research & Development for Idetek Corporation, which was later acquired by Idexx Laboratories, Inc. Dr. Kumar received his bachelor's degree in chemistry from Occidental College. After joint studies at Stanford University and the California Institute of Technology, he received his Ph.D. from Caltech in 1991. He also completed a post-doctoral fellowship at Harvard University in 1993. Dr. Kumar also serves as a director of Aeolus Pharmaceuticals.

Dr. Anderson has been Chief Operating Officer since February 2004. From April 2003 through March 2004, Dr. Anderson served as our Vice President, Software Development and Engineering. From April 2000 through April 2003, Dr. Anderson served as our Vice President, Software Development. Dr. Anderson also served as the company's first President from October 1995 to January 1997. Prior to joining CombiMatrix, Dr. Anderson co-founded Acacia Research Corporation, and from January 1993 to August 1997, served as Acacia's Vice President, Research and Development. Dr. Anderson received a B.S.E. in nuclear engineering from the University of Michigan in 1985, an M.S. in applied physics from the California Institute of Technology in 1987, and a Ph.D. in computation and neural systems from the California Institute of Technology in 1993.

Mr. Burell was promoted to Chief Financial Officer in November 2006. Previously, he served as Vice President of Finance from November 2001 through November 2006, and as the company's Controller from February 2000 through November 2001. From May 1999 to February 2001, Mr. Burell served as the Controller for Network Commerce, Inc., a publicly traded technology and infrastructure company located in Seattle. Prior to May 1999, Mr. Burell spent 9 years with Arthur Andersen's Audit and Business Advisory practice in Seattle. Mr. Burell is a certified public accountant in the state of Washington (currently inactive) and holds Bachelor of Sciences degrees in Accounting and Business Finance from Central Washington University. Mr. Burell is a member of the American Institute and Washington Society of Certified Public Accountants.

H. Sho Fuji has been Vice President of Engineering and Production since August 2004 and has been with CombiMatrix since October 2000. Mr. Fuji had over 15 years of experience in the integrated circuit and MEMS fields before joining CombiMatrix, most recently as Laboratory Manager for the Washington Technology Center's Microfabrication Laboratory from 1994 to 2000. He previously held management and process development positions at Materials Research Corporation, Boeing's High Technology Center, and GAIN Semiconductor Corporation. Mr. Fuji received his B.S. in Materials Science and Engineering from MIT and a M.S. in Materials Science from Stanford University.

Dr. Mohammed is a recognized world leader in genome and microarray technologies and is a frequent keynote speaker both nationally and internationally. Dr. Mohammed received his Ph.D. degree with a double major in molecular immunology and molecular genetics from the University of Guelph, Canada. He completed postdoctoral training at the University of California, Los Angeles, first in the department of molecular immunology and genetics and then as a clinical fellow in cytogenetics. Dr. Mohammed then continued his clinical cytogenetics training at Baylor college of Medicine, Houston and was appointed Director of Research and Development at Spectral Genomics Inc., Houston where he was instrumental in pioneering the first commercially available whole genome BAC array. After developing the microarray CGH platform at Spectral Genomics Inc. and establishing an extensive international network of collaborative research and development, Dr. Mohammed was recruited by Quest Diagnostics Incorporated, North America's largest clinical reference laboratory where he was the Director of the department of Advanced Technologies. He is the holder of multiple patents in the fields of molecular immunology and genomic microarray technologies. In addition to his role at CMDX, Dr. Mohammed serves as an ambassador of sciences to the Toronto Genome Center, of the renowned Toronto Hospital for Sick Kids.